ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / IPSC
LCTX (22) CABA (33) FATE (36) OCGN (25) ⌘ Pro Terminal →

Century Therapeutics Inc. (IPSC) — RQD Stock Rating Cockpit

$1.47 +0.69% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.47

Century Therapeutics Inc. (IPSC) carries a Roarable Rating of E (Strong Sell) with 18/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (18/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE E • RED ALERT Cap $264.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IPSC Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IPSC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Century Therapeutics Inc. (NASDAQ: IPSC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 18/100 at a spot price of $1.47 (+0.69% 1D, market cap $264.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IPSC ranks #1006 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IPSC compare to LCTX and CABA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IPSC carries a Roarable E (18/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -14.1%. By comparison, LCTX (Lineage Cell Therapeutics Inc.) holds a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $260.5M) and CABA (Cabaletta Bio Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $268.7M). Among the 5-stock peer group, IPSC leads on earnings multiple (N/A) while IPSC leads on capital efficiency (-14.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IPSC?
▼

Per IPSC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001850119), Century Therapeutics Inc. generated $109.2M in revenue (+1556.8% YoY), -$9.6M in net income, and -$104.7M in free cash flow against $223.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.47 (-0.07%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (18/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510018
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (3)Whales (4)SEC (5)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-17.7% Base Target
$3 Bull$1 Base$1 Bear
📬 FREE IPSC RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IPSC)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (18/100 Composite)
🔍 WHY IPSC SCORES 18/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+6/20 pts (33% of score)

FRED Regime × Technicals: 40% of 52W Range • RSI-14 at 44.2 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+5/20 pts (28% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
15
Grade E$1.44+2.1% Next Q
Q2 (-2Q)
16
Grade E$1.47-3.4% Next Q
Q3 (-1Q)
18
Grade E$1.42+3.5% Next Q
Current
18
Grade E$1.47-12.2% Hist 90D α
Trajectory: E (15) → E (18)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IPSC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IPSC currently carries a cautious 18/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.73) and Max Pain ($1.54) forces dealer call-delta covering toward $3.19.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IPSC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IPSC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 18%NO 82%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
44.230 Oversold · 70 Hot
ALTMAN-Z SHIELDDISTRESS RISK (<1.8)
0.20>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
3 / 99-Pt Accounting
52-WEEK LASER RANGE40% OF RANGE
L: $0$1.47H: $3
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 0 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 7 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 11 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on IPSC

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (15)

-14.1% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (25)

Altman-Z 0.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (22)

7/40 institutional & smart-money positioning score with 6/20 macro alignment.

Bull Case: Why Buyers Like IPSC
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IPSC)

  • ✓Walkthrough of IPSC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
IPSC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -35.81%▼ DESCENDING CHANNEL
2026-11-02O $1.50H $1.50L $1.46C $1.47VOL 1.45M
RES: $1.91SUP: $0.99SMA50: $1.73SMA200: $2.09
$2.64$2.26$1.87$1.49$1.10RES $1.91SUP $0.99$1.472026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IPSC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IPSC Butterfly Map → + Track IPSC →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IPSC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IPSC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IPSC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IPSC)

Health Care Rank #1006 of 1016 ⚔️ LCTX vs IPSC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IPSC vs. LCTX, CABA, FATE, OCGN)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Century Therapeutics Inc. (IPSC) ranks #1006 by composite RQD confidence (18/100, grade E) and #536 by equity capitalization ($264.4M). Within this direct 5-issuer industry benchmark cohort, IPSC leads on earnings valuation at N/A trailing P/E, while IPSC leads on capital efficiency and profitability with -14.1% ROIC and — gross margin. FATE currently holds the highest overall quantitative score in the immediate peer group at 36/100 (D-) compared with IPSC at 18/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
IPSC ACTIVE
Century Therapeutics Inc.
E 18/100 — — -14.1% +0.69% $264.4M Benchmark Subject
LCTX
Lineage Cell Therapeutics Inc.
E 22/100 — — -35.0% -2.91% $260.5M /lctx-vs-ipsc →
CABA
Cabaletta Bio Inc.
E 33/100 — — -35.0% -4.73% $268.7M /caba-vs-ipsc →
FATE
Fate Therapeutics Inc.
D- 36/100 — — -35.0% -4.15% $260.0M /fate-vs-ipsc →
OCGN
Ocugen Inc.
E 25/100 — — -35.0% -5.58% $252.4M /ocgn-vs-ipsc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001850119

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Century Therapeutics Inc. (IPSC) reported GAAP revenue of $109.2M (+1556.8% vs. FY2024 revenue of $6.6M , and +4784.3% cumulative change since FY2023) , GAAP net income of -$9.6M, operating cash flow of -$103.9M, and free cash flow of -$104.7M (+5.0% YoY). On the balance sheet, IPSC closed FY2025 with $223.7M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $109.2M -$9.6M -$103.9M -$104.7M $223.7M —
FY2024 (FY) 2024-12-31 $6.6M -$126.6M -$110.1M -$110.3M $353.2M —
FY2023 (FY) 2023-12-31 $2.2M -$136.7M -$88.3M -$88.3M — —

3. IPSC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IPSC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Century Therapeutics Inc. (NASDAQ: IPSC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 18/100 at a spot price of $1.47 (+0.69% 1D, market cap $264.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IPSC ranks #1006 in composite RQD confidence.

How does IPSC compare to LCTX and CABA in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IPSC carries a Roarable E (18/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -14.1%. By comparison, LCTX (Lineage Cell Therapeutics Inc.) holds a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $260.5M) and CABA (Cabaletta Bio Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $268.7M). Among the 5-stock peer group, IPSC leads on earnings multiple (N/A) while IPSC leads on capital efficiency (-14.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IPSC?

Per IPSC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001850119), Century Therapeutics Inc. generated $109.2M in revenue (+1556.8% YoY), -$9.6M in net income, and -$104.7M in free cash flow against $223.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IPSC trading relative to its 50-day, 200-day, and 52-week technical levels?

IPSC last traded at $1.47 (+0.69% on volume of 951,161 shares), positioning the stock -15.03% below its 50-day simple moving average ($1.73) and -29.67% below its 200-day simple moving average ($2.09). Across its 52-week range of $0.44 to $3.04, IPSC sits at the 39.6% percentile with a 14-day RSI of 44.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.29 to $1.65).

IPSC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell IPSC stock right now?

Century Therapeutics Inc. (IPSC) currently earns a Roarable Rating of E (Strong Sell — SELL) with 18/100 RQD Confidence. Stretched risk/reward at current multiples (-14% return on capital) under elevated 10-year interest-rate pressure.

What is IPSC's 12-month price target and RQD AI Jury consensus?

IPSC's 12-month base price target is $1.21 (range $0.94 to $3.19), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: IPSC RQD Cockpit IPSC 12M Forecast IPSC Earnings & Move IPSC Dividends & DRIP IPSC Insiders & 13F IPSC Whale Options IPSC Profit Sankey IPSC News & Why
ROARABLE RATING BRIEF • RQD 18/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

IPSC — Century Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:39:39Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, IPSC scores 18 out of 100, grade E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The Fundamental Cash Engine pillar scores 0 out of 20, reflecting ROIC of -14.1% and FCF yield of 0%. The Whale 13F Flow pillar scores 4 out of 20, reflecting institutional accumulation and options positioning. The Insider Conviction pillar scores 3 out of 20, reflecting SEC Form 4 and Congressional PTR cluster flow. The Macro Regime Fit pillar scores 6 out of 20, reflecting a beta of 1.0 and sector sensitivity. The Forensic Balance Sheet pillar scores 5 out of 20, reflecting an Altman Z-Score of 0.2, a Piotroski F-Score of 3/9, and Debt/Equity of 0.5. For a prospective investor, the rating's weakest elements are cash generation and balance sheet strength, which are the pillars most directly tied to downside protection. Upside drivers, if any, are not identified as strengths in the rating itself; the stronger pillars (whale flow, insider flow) are still scored low. Valuation cannot be framed against earnings because P/E and EPS are not available in source data. Any upside thesis must rest on catalysts outside the rated fundamentals, and the source data does not quantify those.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$109.2M$-17.3M$-9.6MN/A$-104.7M$61.9MN/A
FY 2024$6.6M$-138.1M$-126.6MN/A$-110.3M$58.4MN/A
FY 2023$2.2M$-146.5M$-136.7MN/A$-88.3MN/AN/A

Per the SEC financials, operating margin is -15.8%, net margin is -8.8%, and gross margin is 0%. ROIC is -14.1%. Per the Roarable RQD rating, the Altman Z-Score is 0.2 and the Piotroski F-Score is 3/9, with Debt/Equity of 0.5. Reported FY 2025 revenue is well above FY 2024 and FY 2023, but operating and net losses remain negative in every period shown.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the headlines are predominantly market-wire items (Yahoo! Finance Canada, Yahoo Finance Australia, TradingView) with no detailed event content in the summaries. The most specific item is that Century Therapeutics plans to attend the 2026 Jefferies Global Healthcare Conference in London. Other items are seasonal return charts and an earnings-estimate headline for Q3'26 showing a revenue estimate of 0 USD. Risk watch items include the negative cash flow and operating losses in the financials, and the Q3'26 revenue estimate of 0 USD. Per the Butterfly Supply-Chain Graph, the supply-chain status is NONE, with no butterfly links and no proprietary signals.

Open Questions

  • What are the company's specific products, pipeline assets, and commercial revenue sources behind the FY 2025 revenue of $109.2M?
  • What is the reason for the sharp change in revenue between FY 2024 ($6.6M) and FY 2025 ($109.2M), and is it recurring?
  • What are the company's debt obligations, given that debt is listed as N/A in every reported period?
  • What is the FCF and cash runway outlook, given FY 2025 FCF of $-104.7M against cash of $61.9M?
  • What are the valuation metrics (P/E, EV/EBITDA, EPS) that would allow the market price of 1.46 to be assessed against earnings?

IPSC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Century Therapeutics Inc. (IPSC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IPSC Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IPSC Bull vs. Bear Conversation Board — What's Your Call at $1.47?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IPSC 🐻 67% BEARISH CONVICTION
1. Pick Your Side on IPSC:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.28 (-12.3%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is IPSC (E • RQD 18/100) a Buy at $1.46?

Welcome to the IPSC (Century Therapeutics Inc.) Roar Pit. Current RQD Composite is 18/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.18 (-19.2%)
Spot @ $1.46

Pump the brakes on IPSC — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on IPSC, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Century Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.85 (+26.7%)
Spot @ $1.46

IPSC cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on IPSC, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $1.46 (52-wk range $0.44 - $3.04), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%